Manuscripts and Publications

Filters: Keyword is Young Adult and Author is Mulligan, Kathleen  [Clear All Filters]
Publication
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, D Harris R et al..  2018.  Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.. Clin Infect Dis. 66(2):220-228.
Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2014.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.
Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD et al..  2012.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB.  2018.  Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB.  2012.  Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.. J Clin Endocrinol Metab. 97(11):4004-13.
Mulligan K, D Harris R, Monte D, Stoszek S, Emmanuel P, Hardin DS, Kapogiannis BG, Worrell C, Meyer WA, Sleasman J et al..  2010.  Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.. Clin Infect Dis. 50(1):106-14.
Mulligan K, D Harris R, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, Monte D, Sleasman J, Wilson CM, Aldrovandi GM.  2012.  Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.. Clin Infect Dis. 55(3):461-8.
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G et al..  2017.  An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.. J Acquir Immune Defic Syndr. 74(1):21-29.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N et al..  2017.  Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.. Clin Infect Dis. 64(3):317-325.
Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG et al..  2020.  Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.. Clin Infect Dis. 70(4):687-691.
Ruan A, Tobin NH, Mulligan K, Rollie A, Li F, Sleasman J, Aldrovandi GM.  2016.  Brief Report: Macrophage Activation in HIV-Infected Adolescent Males Contributes to Differential Bone Loss by Sex: Adolescent Trials Network Study 021.. J Acquir Immune Defic Syndr. 72(4):372-5.